Implication of the JAK-STAT Pathway in Gliomagenesis: A Target for Therapy?
|Elias A El Habr1*, Christos Adamopoulos2, Georgia Levidou1, Vassilis Samaras3, Athanasios Zisakis3, Penelope Korkolopoulou1 and Christina Piperi2|
|1First Department of Pathology, Laiko Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece|
|2Department of Biological Chemistry, National and Kapodistrian University of Athens, Medical School, Athens, Greece|
|3Department of Pathology and Neurosurgery, Red Cross Hospital, Greece|
|Corresponding Author :||Elias A El-Habr
75 Mikras Asias street
First Department of Pathology, National and Kapodistrian University of Athens
Medical School, 11527 Athens, Greece
|Received February 21, 2013; Accepted April 17, 2013; Published April 19, 2013|
|Citation: El Habr EA, Adamopoulos C, Levidou G, Samaras V, Zisakis A, et al. (2013) Implication of the JAK-STAT Pathway in Gliomagenesis: A Target for Therapy? J Neurol Disord 1:112. doi: 10.4172/2329-6895.1000112|
|Copyright: © 2013 El Habr EA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at
Pubmed Scholar Google
Gliomas, being the most prevalent and aggressive malignancy of the central nervous system, are associated with poor prognosis and very low survival rates. Failure of malignant glioma cells to respond to conventional cancer therapies is attributed to their infiltrating and immunosuppressive phenotype along with increased molecular heterogeneity. Current evidence implicates aberrant JAK-STAT signaling and expression of STAT inhibitors in the molecular pathogenesis of gliomas. This review provides a critical account of recent evidence regarding JAK-STAT signaling components in gliomagenesis, highlighting the potential therapeutic benefits and perspectives of targeting this pathway.